Benaroya Research Institute, UW Immunology
Director, Immune Tolerance Network
Email: firstname.lastname@example.org | Phone: 206.342.6515
The Immune Tolerance Network (ITN) is a large collaborative clinical and translational research effort, involving several hundred investigators world-wide, exploring innovative therapeutic options for human autoimmune disease, transplantation, and allergy. ITN clinical trials utilize immune modulation and/or replacement strategies designed to replace deleterious immune responses, such as immune attacks on islet cells or rejection of transplanted tissue, with durable protection from such immune damage. Within this portfolio, we engage with leading research laboratories to develop biomarkers of disease prognosis and response to therapy. Our diabetes research studies utilize a variety of experimental biological therapies to achieve deletion, deviation, or reprogramming of immune effector cells, in concert with expansion of immune regulatory cells, designed to salvage functional pancreatic beta cells and prevent recurrence of diabetes after transplantation of new islets, engineered beta cells, or stem cells.